BIBLIOGRAFIA
Abou-Khalil B., Lazenby B., Long-term experience with levetiracetam, Epileptic Disord 2003; 5 (Suppl 1): S33–S37.
Abou-Khalil B., Levetiracetam in the treatment of epilepsy, Neuropsychiatric Disease and Treatment 2008:4(3) 507–523.
Avoli M., Rogawski M.A., Avanzini G.: Generalized epileptic disorder: an update, Epilepsia 42: 445-457, 2001.
Ben-Menachem E, Falter U., Efficacy and tolerability of levetiracetam 3000 mg in patients with refractory partial seizures: a multicenter, double-blind, responder- selected study evaluating monotherapy, Epilepsia 2000;41:1276–83.
Berg A.T., Shinnar S, Hauser W.A., Alemany M., Shapiro E.D., Salomon M.E., Crain M.F., A prospective study of recurrent febrile seizure, N. Engl. J. Med. 327:
1122-1127, 1992.
Berkovic S.F., Knowlton R.C., Leroy R.F., Schiemann J., Falter U., Levetiracetam N01057 Study Group, Placebo-controlled study of levetiracetam in idiopathic generalized epilepsy, Neurology 2007, 69, 1751—1760.
Binnie C.D., Prior P.F., Electroencephalography, J. Neurol. Neurosurg.
Psychiatry 1994, 57 (11): 1308-1319.
Blume W.T., Luders H.O., Mizrahi E., Tassinari C., Van Emde Boas W. and Engel Jr. J., Glossary of Descriptive Terminology for Ictal Semiology: Report of the ILAE Task Force on Classification and Terminology, Epilepsia, 42(9):1212–
1218, 2001.
Brodie M.J., Perucca E., Ryvlin P., Ben-Menachem E., Meencke H.J. for Levetiracetam Monotherapy Study Group, Comparison of levetiracetam and controlled-release carbamazepine in newly diagnosed epilepsy, 2007, Feb 6;68(6):402-8.
Neurology
Cereghino J.J., Biton V., Abou-Khalil B., Dreifuss F., Gauer L.J.; Leppik I. and the United States Levetiracetam Study Group, Levetiracetam for partial seizures:
results of a double-blind, randomized clinical trial, Neurology 2000; 55: 236–42.
Commission on Classification and Terminology of the ILAE 1981, Proposal for revised clinical and electroencephalographic classification of epileptic seizures, Epilepsia 22: 489–501.
Commission on Classification and Terminology of the ILAE 1985, Proposal for classification of epilepsies and epileptic syndromes, Epilepsia 26: 268–278.
Commission on Classification and Terminology of the ILAE 1989, Proposal for revised classification of epilepsies and epileptic syndromes, Epilepsia 30: 389–
399.
Commission on Classification and Terminology of the ILAE 2008, Report of the Commission on Classification and Terminology: Update and Recommendations.
Crowder K.M., Gunther J.M., Jones T.A., Hale B.D., Zhang H.Z., Peterson M.R., Scheller R.H., Chavkin C., Bajjalieh S.M., Abnormal neurotransmission in mice lacking synaptic vesicle protein 2A (SV2A), Proc Natl Acad Sci USA 1999, 96:
15268-15273.
De Smedt T., Raedt R., Vonck K., Boon P., Levetiracetam: The Profile of a Novel Anticonvulsant Drug - Part I: Preclinical Data, CNS Drug Reviews 2007, Vol.13, No. 1, pp. 43–56 (a).
De Smedt T., Raedt R., Vonck K., Boon P., Levetiracetam: Part II, the Clinical Profile of a Novel Anticonvulsant Drug, CNS Drug Reviews 2007, Vol. 13, No. 1, pp. 57–78 (b).
Engel Jr. J., A proposed diagnostic scheme for people with epileptic seizures and with epilepsy: report of the ILAE Task Force on Classification and Terminology.
Epilepsia 42(6):796–803, 2001.
Engel Jr. J., ILAE classification of epilepsy syndromes, Epilepsy Research 70S (2006): S5–S10.
Favale E., Seitun A., Epilessie e crisi epilettiche occasionali, in Neurologia di Fazio e Loeb, Loeb C., Favale E., pp. 1137-1207, Società Editrice Universo, 2002.
Fisher R.S., Van Emde B.W., Blume W., Elger C., Genton P., Lee P., Engel J.
Epileptic seizures and epilepsy: definitions proposed by the International League Against Epilepsy (ILAE) and the International Bureau for Epilepsy (IBE).
Epilepsia 2005 Apr; 46[4]: 470- 472.
Gambardella A., Labate A., Colosimo E., Ambrosio R., Quattrone A., Monotherapy for partial epilepsy: focus on levetiracetam, Neuropsychiatric Disease and Treatment 2008:4(1) 33–38.
Gastaut H. Clinical ed elettroencephalographic classification of epileptic seizures.
Epilepsia. 1970; [11]:102-103.
Glauser T., Ben-Menachem E., Bourgeois B., Cnaan A., Chadwick D., Guerreiro C., Kalviainen R., Mattson R., Perucca E., Tomson T., ILAE Treatment Guidelines: Evidence-based Analysis of Antiepileptic Drug Efficacy and Effectiveness as Initial Monotherapy for Epileptic Seizures and Syndromes, Epilepsia 2006, 47(7): 1094–1120.
Glauser T.A., Ayala R., Elterman R.D., Mitchell W.G., Van Orman C.B., Gauer L.J., Lu Z., Double-blind placebo-controlled trial of adjunctive levetiracetam in pediatric partial seizures, Neurology 2006, 66, 1654—1660.
Gloor P., Consciousness as a neurological concept in epileptology: a critical review, Epilepsia 27, Suppl.2: S14-26, 1986.
Gloor P., Fariello R.G. Generalized epilepsy: some of its cellular mechanisms differ from those of focal epilepsy, Trends Neurosci. 11: 63-68, 1988.
Goldensohn E., The relevance of secondary epileptogenesis to the treatment of epilepsy: kindling and the mirror focus, Epilepsia 25(suppl 2):156, 1984.
Harden C., Safety Profile of Levetiracetam, Epilepsia, 42(Suppl. 4):36–39, 2001.
Hauser WA., The prevalence and incidence of convulsive disorders in children, Epilepsia 1994; 35(Suppl 2):S1–S6.
Janz R., Goda Y., Geppert M., Missler M., Sudhof T.C., SV2A and SV2B function as redundant Ca2+-regulators in neurotransmitter release, Neuron 1999, 24:
1003-1016.
Jensen S., Giorgi F.S., Iudice A., La personalizzazione della cura in epilessia, Primula, 2008.
Kanner A.M., Depression in epilepsy: prevalence, clinical semiology, pathogenic mechanisms and treatment, Biol. Psychiatry 2003; 54: 388-398.
Kinirons P., McCarthy M., Doherty C.P., Delanty N., Predicting drug-resistant patients who respond to add-on therapy with levetiracetam, Seizure (2006) 15, 387-392.
Klitgaard H., Levetiracetam: The Preclinical Profile of a New Class of Antiepileptic Drugs?, Epilepsia, 42(Suppl. 4):13–18, 2001.
Kohrman M.H., What is Epilepsy? Clinical Perspectives in the Diagnosis and Treatment, J Clin Neurophysiol 2007; 24: 87–95.
Kwan P., Brodie M.J., Early identification of refractory epilepsy, N Engl J Med 2000; 342: 314–319.
Lynch B.A., Lambeng N., Nocka K., Kensel-Hammes P., Bajjalieh S.M., Matagne A., Fuks B., The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam, Proc Natl Acad Sci USA 2004, Jun 29; 101(26):
9861-6.
Loscher W., Reissmuller E., Ebert U., Anticonvulsant efficacy of gabapentin and levetiracetam in phenytoinresistant kindled rats, Epilepsy Res 2000, 40:63-77.
Lowenstein D.H., Alldredge B.K., Status epilepticus., N Engl J Med 1998;
338:970–976.
Lowenstein D.H., Status epilepsticus: an overview of the clinical problem, Epilepsia 40: S3-8; discussion: S20-22, 1999
Lowenstein H.L., Crisi epilettiche ed epilessia, in Harrison Principi di Medicina Interna, Kasper, Brawnwald, Fauci, Hauser, Longo, Jameson, 16th ed., pp. 2661- 2678, McGraw-Hill, 2005.
Marson A.G., Hutton J.L., Leach J.P., Castillo S., Schmidt D., White S., Chaisewikul R., Privitera M., Chadwick D.W., Levetiracetam, oxcarbazepine, remacemide and zonisamide for drug resistant localization-related epilepsy: a systematic review, Epilepsy Res. 2001 Sep; 46(3): 259-70.
Marson A.G., Al-Kharusi A.M., Alwaidh M., Appleton R., Baker G.A., Chadwick D.W., Cramp C., Cockerell O.C., Cooper P.N., Doughty J., Eaton B., Gamble C., Goulding P.J., Howell S.J., Hughes A., Jackson M., Jacoby A., Kellett M., Lawson G.R., Leach J.P., Nicolaides P., Roberts R., Shackley P., Shen J., Smith D.F., Smith P.E., Smith C.T., Vanoli A., Williamson P.R.; SANAD Study group;
The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial, Lancet. 2007 Mar 24;369(9566):1000-15 (a).
Marson A.G., Al-Kharusi A.M., Alwaidh M., Appleton R., Baker G.A., Chadwick D.W., Cramp C., Cockerell O.C., Cooper P.N., Doughty J., Eaton B., Gamble C., Goulding P.J., Howell S.J., Hughes A., Jackson M., Jacoby A., Kellett M., Lawson G.R., Leach J.P., Nicolaides P., Roberts R., Shackley P., Shen J., Smith D.F., Smith P.E., Smith C.T., Vanoli A., Williamson P.R.; SANAD Study group;
The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trial, Lancet. 2007 Mar 24;369(9566):1016-26 (b).
Matsumoto H., Ajmone-Marsan C., Cortical cellular phenomena in experimental epilepsy: interictal manifestation, Exp. Neurol. 9: 286-304, 1964.
Merlis J.K. Proposal for an international classification of epilepsies. Epilepsia 1970;11: 114-119
Monaco F., Mula M., I farmaci anticonvulsivanti in epilessia, XXXVIII Congresso della Società Italiana di Neurologia Firenze (2007)
Nicolson A., Lewis S.A., Smith D.F., A prospective analysis of the outcome of levetiracetam in clinical practice, Neurology 2004 Aug 10;63(3): 568-70.
Noachtar S., Andermann E., Meyvisch P., Andermann F., Gough W.B., Schiemann Delgado J., N166 levetiracetam study Group, Levetiracetam for the treatment of idiopathic generalized epilepsy with myoclonic seizures, Neurology 2008, 70, 607-616.
Nordli D.R., Usefulness of video-EEG monitoring, Epilepsia 2006; 47 (Suppl 1):
26-30.
Peltola J., Peltola M., Auvinen A., Keranen T., Liimatainen S., Kharazmi E., Fallah M., Clinical predictors in patients with refractory epilepsy exposed to levetiracetam: a single-center study, Acta Neurol Scand 2008: 117: 332–336.
Perucca E., Definition of pharmacological intractability (drug resistance), Epilepsia 1997, 38(Suppl. 3): 102.
Perucca E., Current Trends in Antiepileptic Drug Therapy, Epilepsia 2003, 44(Suppl. 4): 41–47.
Perucca E., An Introduction to Antiepileptic Drugs, Epilepsia 2005, 46 (Suppl. 4):
31–37.
PNLG, Diagnosi e trattamento delle epilessie, ISS, 2006.
Privitera M., Efficacy of Levetiracetam: A Review of Three Pivotal Clinical Trials, Epilepsia, 42(Suppl. 4):31–35, 2001.
Radtke R.A., Pharmacokinetics of Levetiracetam, Epilepsia, 42(Suppl. 4):24–27, 2001.
Ropper A.H., Brown R.H., Adams and Victor’s Principles of Neurology. 8th ed., McGraw-Hill, 2005.
Rosenfeld W.E., Benbadis S., Edrichc P., Tassinari C.A., Hirsche E., Levetiracetam as add-on therapy for idiopathic generalized epilepsy syndromes with onset during adolescence: analysis of two randomized, double-blind, placebo-controlled studies, Epilepsy Research (2009) 85, 72—80.
Schomer D.L., A EEG telemetry: how good is it?, J. Clin. Neurophysiol. 2006, 23 (4): 294-305.
Scrimieri R., Le immagini dell’epilessia fra mito e scienza, Psychofenia 2003, vol.
VI, n. 9.
Seino M. Classification criteria of epileptic seizures and syndromes, Epilepsy Res. 2006 Aug.70 Suppl 1: S27-33.
Semah F., Ryvlin P., Can we predict refractory epilepsy at the time of diagnosis?, Epileptic Disord 2005; 7 (Suppl. 1): S10-S13
Shorvon S.D., Lowenthal A., Janz D., Bielen E. and Loiseau P. for the European Levetiracetam Study Group, Multicenter double-blind,randomized, placebo- controlled trial of levetiracetam as add-on therapy in patients with refractory partial seizures. Epilepsia 2000;41:1179–86.
Specchio L.M., Beghi E., Should antiepileptic drugs be withdrawn in seizure-free patients?, CNS Drugs 2004;18(4): 201-12.
Stefan H., Halàsz P., Gil-Nagel A., Shorvon S., Bauer G., Ben-Menachem E., Perucca E., Gregor Wieser H., Steinlein O., Recent advances in the diagnosis and treatment of epilepsy, European Journal of Neurology 2001, 8: 519-539
Stefan H., Lopes da Silva F.H., Loscher W., Schmidt D., Perucca E., Brodie M.J., Boon P.A.J.M., Theodore W.H., Moshé S.L., Epileptogenesis and rational therapeutic strategies, Acta Neurol Scand 2006: 113: 139–155.
Wolf P., Basic principles of the ILAE syndrome classification, Epilepsy Res. 2006 Aug 70 Suppl: S20-26.
Xu T., Bajjalieh S.M., SV2 modulates the size of the readily releasable pool of secretory vesicles, Nat Cell Biol 2001, 3:691-698.
